Local Tranexamic Acid During Vaginal Hysteractomy to Reduce Blood Loss
Launched by MEIR MEDICAL CENTER · Feb 16, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether using a medication called tranexamic acid during vaginal hysterectomy (a surgery to remove the uterus) can help reduce blood loss during the operation. Tranexamic acid is known to help with bleeding, and the researchers want to see if giving it locally (directly at the surgery site) before the procedure can make a difference.
If you are a woman between the ages of 20 and 90 and are scheduled for a vaginal hysterectomy, you may be eligible to participate in this trial. However, if you have conditions that cause heavy bleeding, know that you are sensitive to tranexamic acid, or require it during surgery due to bleeding, you may not qualify. Participants can expect to receive the usual care for their surgery, with the added possibility of receiving tranexamic acid to help manage blood loss. This trial is currently looking for volunteers to help determine the effectiveness of this approach.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 20-90 years old female patients going through vaginal hysterctomy
- Exclusion Criteria:
- • massive bleeding during operation due to major vessles injury
- • known coagulopathies
- • sensitivity to tranexamic acid
- • medical need in tranexamic acid administration during operation due to bleeding
About Meir Medical Center
Meir Medical Center is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. As a prominent sponsor of clinical studies, Meir Medical Center is committed to fostering collaboration among healthcare professionals, researchers, and patients to explore new therapies and treatment modalities. With a focus on ethical practices and patient safety, the center aims to contribute significantly to the scientific community while enhancing the quality of care provided to its diverse patient population. Through its robust infrastructure and multidisciplinary approach, Meir Medical Center stands at the forefront of medical innovation, driving progress in various therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kfar Saba, , Israel
Kfar Saba,, , Israel
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials